From: Ibrutinib in B-cell lymphoma: single fighter might be enough?
 | Ibrutinib | Ibrutinib-Rituximab | Ibrutinib-Chemoimmunotherapy | Ibrutinib-Venetoclax |
---|---|---|---|---|
TN- CLL | (Burger et al. 2015) [3] 269 pts with a median age of 73 years; Regimen, ibrutinib 560Â mg per day Outcome, 18.4-month PFS not reached, 2-year OS 98%, ORR 86%. | (Shanafelt et al. 2019)8 [3] 354 pts aged 70Â years or younger; Regimen, ibrutinib per day, 6 cycles rituximab; Outcome, 33.6-month PFS 89.4%, OS 98.8%; 3-year PFS among pts with IGHV mutation 87.7%. | (Shanafelt et al. 2019) [48] 175 pts aged 70Â years or younger; Regimen, ibrutinib per day, 6 cycles of fludarabine, cyclophosphamide and rituximab; Outcome, 33.6-month PFS 72.9%, OS 91.5%; 3-year PFS among pts with IGHV mutation 88%. | (Jain et al. 2019) [60] 80 high-risk and older pts with CLL; Regimen, ibrutinib 420Â mg once daily for 3 cycles, venetoclax (weekly dose escalation to 400Â mg once daily); Outcome, CR 96% after 18 cycles, and 69% had remission with undetectable MRD; 1-year PFS and OS were 98% and 99%. |
R/R MCL | (Wang et al. 2013)17 111 pts with a median age of 68 years and 86% had intermediate or high-risk MCL; Regimen, ibrutinib 560 mg per day Outcome, ORR 68% (CR 21%, PR 47%); 15.3-month PFS was 13.9 months, 18-month OS 58%. | (Wang et al. 2016)41 50 pts with the median number of previous regimens were three; Regimen, ibrutinib 560 mg per day, rituximab 375 mg/m2 once per week during cycle1, on day 1 of cycles 3–8, and thereafter once daily another cycle up to 2 years; Outcome, 16.5-month ORR 88%, CR 44%, PR 44%. | (Karmali et al. 2019)52 36 pts with CR or PR to frontline chemo-immunotherapy +/- auto-SCT ; Regimen, Received I-M 560 mg/day for up to 4 years; Outcome, I-M is feasible in these pts with manageable toxicities related to the known safety profile of Ibrutinib, but the PFS and OS data are needed larger clinical studies to access. | (Tam et al. 2018)54 24 pts with previously untreated MCL and 75% had high-risk prognostic score; Regimen, Ibrutinib 560 mg/day, venetoclax was weekly increasing dose to 400 mg/day after 4 weeks; Outcome, 16-week CR 42%, 78% of the pts with responses were estimated to have ongoing responses at 15 months. |